Physician profile
Kadie E Leach
NPI 1497707566
$4,963.73
in general payments reported to CMS, 2019-2025
30 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $1,016 · 2021: $766 · 2022: $538 · 2023: $708 · 2024: $808 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $818.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $406.67 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $269.50 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $259.44 | 2022-2025 | |
| Abbott Laboratories | $219.48 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $218.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $208.14 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Arbor Pharmaceuticals, INC. | $163.62 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.55 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $155.68 | 2020-2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $132.61 | 2023-2025 | Edarbi, Edarbi |
| Amarin Pharma, INC. | $126.44 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $121.38 | 2022-2024 | Hetlioz, Fanapt |
| Horizon Therapeutics Plc | $111.92 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $95.37 | 2022-2024 | Trelegy Ellipta |
| Hikma Pharmaceuticals USA | $95.23 | 2019-2021 | |
| Dexcom, INC. | $67.10 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $59.62 | 2021 | |
| Allergan, INC. | $39.92 | 2019-2020 | |
| Abbvie INC. | $35.19 | 2021-2025 | |
| Medtronic, INC. | $35.18 | 2024 | Endurant Iis |
| Novartis Pharmaceuticals Corporation | $28.39 | 2022 | |
| Eyevance Pharmaceuticals LLC | $22.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.29 | 2021 | |
| Astellas Pharma US INC | $18.96 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $15.19 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.09 | 2022 | |
| Phadia US INC. | $14.96 | 2019 | |
| Gilead Sciences, INC. | $13.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kadie Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.